These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 23055747)

  • 1. Denosumab: a new option in the treatment of bone metastases from urological cancers.
    Yuasa T; Yamamoto S; Urakami S; Fukui I; Yonese J
    Onco Targets Ther; 2012; 5():221-9. PubMed ID: 23055747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
    Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
    Fizazi K; Carducci M; Smith M; Damião R; Brown J; Karsh L; Milecki P; Shore N; Rader M; Wang H; Jiang Q; Tadros S; Dansey R; Goessl C
    Lancet; 2011 Mar; 377(9768):813-22. PubMed ID: 21353695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
    Gül G; Sendur MA; Aksoy S; Sever AR; Altundag K
    Curr Med Res Opin; 2016; 32(1):133-45. PubMed ID: 26451465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of RANKL-Targeted Therapy in Immunity and Cancer.
    Cheng ML; Fong L
    Front Oncol; 2014 Jan; 3():329. PubMed ID: 24432249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
    Stopeck AT; Lipton A; Body JJ; Steger GG; Tonkin K; de Boer RH; Lichinitser M; Fujiwara Y; Yardley DA; Viniegra M; Fan M; Jiang Q; Dansey R; Jun S; Braun A
    J Clin Oncol; 2010 Dec; 28(35):5132-9. PubMed ID: 21060033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The treatment for cancer with bone metastases -whether to use zoledoronate or denosumab for bone metastases-].
    Kohno N
    Clin Calcium; 2014 Aug; 24(8):1229-36. PubMed ID: 25065876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.
    Iranikhah M; Wilborn TW; Wensel TM; Ferrell JB
    Pharmacotherapy; 2012 Mar; 32(3):274-84. PubMed ID: 22392458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal and extraskeletal actions of denosumab.
    Sinningen K; Tsourdi E; Rauner M; Rachner TD; Hamann C; Hofbauer LC
    Endocrine; 2012 Aug; 42(1):52-62. PubMed ID: 22581255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of bone metastases in refractory prostate cancer--role of denosumab.
    Paller CJ; Carducci MA; Philips GK
    Clin Interv Aging; 2012; 7():363-72. PubMed ID: 23049248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors.
    Brown-Glaberman U; Stopeck AT
    Biologics; 2012; 6():89-99. PubMed ID: 22532777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
    Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
    Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-RANKL antibody for the management of bone metastasis].
    Yoneda T
    Gan To Kagaku Ryoho; 2011 Sep; 38(9):1439-45. PubMed ID: 21918338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art.
    Clemons M; Gelmon KA; Pritchard KI; Paterson AH
    Curr Oncol; 2012 Oct; 19(5):259-68. PubMed ID: 23144574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab: A comprehensive review.
    Narayanan P
    South Asian J Cancer; 2013 Oct; 2(4):272-7. PubMed ID: 24455656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The RANK-RANKL-OPG System: A Multifaceted Regulator of Homeostasis, Immunity, and Cancer.
    De Leon-Oliva D; Barrena-Blázquez S; Jiménez-Álvarez L; Fraile-Martinez O; García-Montero C; López-González L; Torres-Carranza D; García-Puente LM; Carranza ST; Álvarez-Mon MÁ; Álvarez-Mon M; Diaz R; Ortega MA
    Medicina (Kaunas); 2023 Sep; 59(10):. PubMed ID: 37893470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting RANKL in metastasis.
    Dougall WC; Holen I; González Suárez E
    Bonekey Rep; 2014; 3():519. PubMed ID: 24795813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
    J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative pharmacology of denosumab in patients with bone metastases from solid tumors.
    Perez Ruixo JJ; Doshi S; Sohn W; Chow A
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S85-92. PubMed ID: 25707967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab for the treatment of bone metastases in advanced breast cancer.
    Casas A; Llombart A; Martín M
    Breast; 2013 Oct; 22(5):585-92. PubMed ID: 23759273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.